News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Study of GlaxoSmithKline Platelet Drug, Promacta Halted Due to Clots
May 13, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. regulators said on Wednesday a study among liver-disease patients taking GlaxoSmithKline's (GSK.L)(GSK.N) Promacta treatment for low blood platelets was halted due to blood-clot safety issues.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
GSK
MORE ON THIS TOPIC
Huntington’s disease
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
September 29, 2026
·
4 min read
·
Heather McKenzie
Obesity
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
September 29, 2026
·
2 min read
·
Tristan Manalac
Business
Summit snags $2B investment from AstraZeneca, clearing financial overhang
September 29, 2026
·
3 min read
·
Tristan Manalac
Eye disease
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
September 28, 2026
·
1 min read
·
Gabrielle Masson
